Pharma BD Deal Intelligence
Pfizer paid to consolidate full rights to Exubera in 2006, then killed the product 20 months later and ate a $2.8B write-off — one of the largest pharma product failures on record.
Full analysis, sources & comparables →Nektar (technology partner) characterized the Pfizer buyout as removing partnership friction and giving Exubera a single committed marketer behind a major…
Pfizer paid $1.3bn for full Exubera rights then withdrew the product 21 months later citing $12M sales versus $2bn projected peak - 'first time a licensed…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Pfizer bought out Sanofi WW rights to inhaled insulin Exubera plus Frankfurt insulin facility
Pfizer paid to consolidate full rights to Exubera in 2006, then killed the product 20 months later and ate a $2.8B write-off — one of the largest pharma product failures on record.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Sanofi-Aventis (Exubera worldwide rights) (this deal) | 2006 | $1.4B | 9 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2006 deals · Pfizer Inc. deals